Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
1. An aerosolized composition comprising droplets of a pharmaceutical formulation, wherein prior to aerosolization, the pharmaceutical formulation is a solution or suspension and comprises a mixture of free quinolone antibiotic agent, a quinolone antibiotic agent encapsulated in a plurality of liposomes, and a pharmaceutical excipient; the ratio by weight of the free quinolone antibiotic agent to the encapsulated quinolone antibiotic agent in the pharmaceutical formulation prior to aerosolization is between about 1:10 and about 10:1; and the lipid component of the plurality of liposomes consists of a phospholipid and a sterol.
2. The aerosolized composition of claim 1 , wherein the free quinolone antibiotic agent is a fluoroquinolone and the quinolone antibiotic agent encapsulated in the plurality of liposomes is a fluoroquinolone.
3. The aerosolized composition of claim 1 , wherein the free quinolone antibiotic agent and the quinolone antibiotic agent encapsulated in the plurality of liposomes is independently, ciprofloxacin, enoxacin, gatifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, oxolinic acid, gemifloxacin, or perfloxacin.
4. The aerosolized composition of claim 1 , wherein the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.
5. The aerosolized composition of claim 1 , wherein the phospholipid is a phosphatidylcholine.
6. The aerosolized composition of claim 5 , wherein the phosphatidylcholine is hydrogenated soy phosphatidylcholine (HSPC).
7. The aerosolized composition of claim 5 , wherein the sterol is cholesterol.
8. The aerosolized composition of claim 6 , wherein the sterol is cholesterol.
9. The aerosolized composition of claim 1 , wherein the phospholipid is hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is a fluoroquinolone and the quinolone antibiotic agent encapsulated in the plurality of liposomes is a fluoroquinolone.
10. The aerosolized composition of claim 1 , wherein the phospholipid is a phosphatidylcholine, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.
11. The aerosolized composition of claim 1 , wherein the phospholipid is a phosphatidylcholine, the sterol is cholesterol, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.
12. The aerosolized composition of claim 1 , wherein the phospholipid is hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is ciprofloxacin and the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin.
13. The aerosolized composition of claim 1 , wherein the phospholipid is hydrogenated soy phosphatidylcholine (HSPC), the sterol is cholesterol, the free quinolone antibiotic agent is ciprofloxacin, the quinolone antibiotic agent encapsulated in the plurality of liposomes is ciprofloxacin and the mean diameter of the plurality of liposomes is 0.01 micron to 3.0 microns.
14. The aerosolized composition of claim 1 , wherein the ratio by weight of free quinolone antibiotic agent to the encapsulated quinolone antibiotic agent is between about 1:2 and about 2:1.
15. The aerosolized composition of claim 12 , wherein the ratio by weight of free ciprofloxacin to the encapsulated ciprofloxacin is between about 1:2 and about 2:1.
16. The aerosolized composition of claim 6 , wherein the free quinolone antibiotic agent is ciprofloxacin.
17. The aerosolized composition of claim 1 , wherein the aerosol has been generated by a nebulizer.
18. The aerosolized composition of claim 17 , wherein the nebulizer is a single dose nebulizer.
19. The aerosolized composition of claim 1 , wherein the droplets are sized for positioning within the pulmonary membrane.
20. A method for treating a pulmonary infection in a patient in need thereof comprising,
administering the aerosolized composition of claim 1 to the lungs of the patient.
21. A method for treating a pulmonary infection in a patient in need thereof comprising,
administering the aerosolized composition of claim 11 to the lungs of the patient.
22. A method for treating a pulmonary infection in a patient in need thereof comprising,
administering the aerosolized composition of claim 12 to the lungs of the patient.
23. A method for treating a pulmonary infection in a patient in need thereof comprising,
administering the aerosolized composition of claim 15 to the lungs of the patient.
24. The method of claim 20 , wherein the patient is a bronchiectasis patient.
25. The method of claim 21 , wherein the patient is a bronchiectasis patient.
26. The method of claim 22 , wherein the patient is a bronchiectasis patient.
27. The method of claim 23 , wherein the patient is a bronchiectasis patient.
28. The method of claim 22 , wherein the pulmonary infection is a Pseudomonas aeruginosa infection.
29. The method of claim 23 , wherein the pulmonary infection is a Pseudomonas aeruginosa infection.
30. The method of claim 26 , wherein the pulmonary infection is a Pseudomonas aeruginosa infection.